Published in Leukemia on December 01, 2000
Whole plant extracts versus single compounds for the treatment of malaria: synergy and positive interactions. Malar J (2011) 1.35
Secondary Metabolites from Plants Inhibiting ABC Transporters and Reversing Resistance of Cancer Cells and Microbes to Cytotoxic and Antimicrobial Agents. Front Microbiol (2012) 0.98
International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood (1997) 20.41
Psychiatric diagnosis in child and adolescent suicide. Arch Gen Psychiatry (1996) 4.78
All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood (1990) 4.36
Depressed adolescents grown up. JAMA (1999) 3.80
Offspring of depressed parents. 10 Years later. Arch Gen Psychiatry (1997) 3.44
Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst (1995) 3.00
Variations in the number and morphology of Langerhans' cells in the epidermal component of squamous cell carcinomas. Arch Dermatol (1989) 2.73
Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood (1998) 2.71
p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood (1994) 2.51
Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol (1997) 2.38
Dog, cat, and human bites: a review. J Am Acad Dermatol (1995) 2.35
Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine? Leuk Res (2011) 2.23
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia (2011) 2.12
Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial. Aliment Pharmacol Ther (2014) 2.11
Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia (2008) 2.10
All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood (1995) 2.04
Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis? Antimicrob Agents Chemother (1995) 2.01
A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer (2011) 1.95
A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med (1995) 1.94
Efficacy of interpersonal psychotherapy for depressed adolescents. Arch Gen Psychiatry (1999) 1.93
Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia. Oncogene (2011) 1.87
Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol (2001) 1.85
Therapy-related acute promyelocytic leukemia. J Clin Oncol (2003) 1.82
Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia (2001) 1.82
Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res (2000) 1.81
Differential carbon dioxide sensitivity in childhood anxiety disorders and nonill comparison group. Arch Gen Psychiatry (2000) 1.78
Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia (2006) 1.77
A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol (1991) 1.75
Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol (2012) 1.69
Prevalence of IgA2 deposits in IgA nephropathies: a clue to their pathogenesis. N Engl J Med (1980) 1.67
A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. J Antimicrob Chemother (1994) 1.64
Brief report: heavy-chain deposition disease. N Engl J Med (1993) 1.63
Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia (2007) 1.63
Distribution of IgA 1 and IgA 2 plasma cells in various normal human tissues and in the jejunum of plasma IgA-deficient patients. Clin Exp Immunol (1978) 1.61
Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia (2000) 1.55
Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group. J Clin Oncol (2000) 1.53
Association between myelodysplastic syndromes and inflammatory bowel diseases. Report of seven new cases and review of the literature. Leukemia (1997) 1.50
Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother (1991) 1.49
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol (1995) 1.49
Chronic and subacute myelomonocytic leukaemia in the adult: a report of 60 cases with special reference to prognostic factors. Br J Haematol (1987) 1.48
Parents' awareness of children's suicide attempts. Am J Psychiatry (1990) 1.48
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia (2007) 1.48
Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol (1995) 1.48
A double-blind evaluation of topical capsaicin in pruritic psoriasis. J Am Acad Dermatol (1993) 1.47
Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases. Br J Haematol (1994) 1.46
Could heart rate variability predict outcome in patients with severe head injury? A pilot study. J Neurosurg Anesthesiol (2001) 1.46
Myocardial uptake of metaiodobenzylguanidine in patients with left ventricular hypertrophy secondary to valvular aortic stenosis. J Nucl Med (1993) 1.45
CEBPA point mutations in hematological malignancies. Leukemia (2005) 1.45
Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM). Bone Marrow Transplant (2000) 1.44
Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. Leukemia (2005) 1.44
Diagnostic value of serum IL-6 level in monoclonal gammopathies. Br J Haematol (1995) 1.43
Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia (2008) 1.43
A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia. J Clin Oncol (1991) 1.42
Comparison of retinol-binding protein and beta 2-microglobulin determination in urine for the early detection of tubular proteinuria. Clin Chim Acta (1982) 1.42
Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood (1998) 1.42
Modulation of the macrophage oxidative burst by Histoplasma capsulatum. J Immunol (1987) 1.42
Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia (2012) 1.42
Multicentric evaluation of the MDR phenotype in leukemia. French Network of the Drug Resistance Intergroup, and Drug Resistance Network of Assistance Publique-Hôpitaux de Paris. Leukemia (1997) 1.41
Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res (1993) 1.41
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. Ann Oncol (2013) 1.41
B-cell chronic lymphocytic leukemia: present status and future directions. French Cooperative Group on CLL. Blood (1991) 1.40
The Attending Nurse: a new role for the advanced clinician. J Child Adolesc Psychiatr Ment Health Nurs (1992) 1.40
N-terminal pro-brain natriuretic peptide levels in patients with non-ST-elevation myocardial infarction. Cardiology (2004) 1.40
Inv(16) may be one of the only 'favorable' factors in acute myeloid leukemia: a report on 19 cases with prolonged follow-up. Leuk Res (1994) 1.39
Reduced fungal contamination of the indoor environment with the Plasmair system (Airinspace). J Hosp Infect (2006) 1.39
[Association of celiac disease and antiphospholipid syndrome]. Presse Med (1998) 1.39
Interferon alpha-2b therapy in refractory adult chronic thrombocytopenic purpura. Br J Haematol (1991) 1.39
Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. J Clin Oncol (2000) 1.39
Maximal blood lactate level acts as a major discriminant variable in exercise testing for coronary artery disease detection in men. Circulation (1996) 1.38
Targeting NF-kappaB in hematologic malignancies. Cell Death Differ (2006) 1.38
Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res (2001) 1.38
Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol (2000) 1.37
Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol (1992) 1.37
Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther (2001) 1.35
Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations. Leukemia (1995) 1.34
Hypoxaemia associated with an enlarged aortic root: a new syndrome? Heart (2005) 1.34
Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer (2003) 1.34
Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer (2001) 1.33
In vivo and in vitro invasiveness of a rat colon-cancer cell line maintaining E-cadherin expression: an enhancing role of tumor-associated myofibroblasts. Int J Cancer (1994) 1.33
All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship. Blood (1990) 1.30
Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia (1993) 1.29
Comparative genotyping of Candida albicans bloodstream and nonbloodstream isolates at a polymorphic microsatellite locus. J Clin Microbiol (2000) 1.27
Expression of the Cdx1 and Cdx2 homeotic genes leads to reduced malignancy in colon cancer-derived cells. J Biol Chem (1998) 1.27
Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia (2005) 1.27
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia (2012) 1.27
Nonvalvular infections of the cardiovascular system. Ann Intern Med (1994) 1.26
Cdx1 promotes differentiation in a rat intestinal epithelial cell line. Gastroenterology (1999) 1.25
Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. J Clin Oncol (1998) 1.23
HSP27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs. Cancer Res (1997) 1.22
Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients. J Antimicrob Chemother (1993) 1.21